86
Participants
Start Date
May 8, 2018
Primary Completion Date
January 31, 2020
Study Completion Date
June 1, 2021
concurrent sorafenib and IMRT, followed sorafenib maintenance
IMRT 40-60Gy/20-30f; concurrent sorafenib 400mg bid po (it can be given to patients in four weeks before IMRT is applied, so that it can control disease during waiting for IMRT); maintenance sorafenib 400mg bid po until disease progress or unacceptable adverse events; six months is recommended but not mandatory.
Bo Chen, Beijing
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OTHER